Phase 2 CLL cladribine studies: previously treated patients
| Study . | No. of patients . | Median no. of prior therapies . | Cladribine doses and other agents . | Response, % . | Median duration, mo . | |
|---|---|---|---|---|---|---|
| OR . | CR . | |||||
| Saven et al (1991)71 | 90 | 2 | A, B | 44 | 4 | 4 |
| Tallman et al (1995)75 | 26 | 2 | A | 31 | 0 | 16 |
| Robak et al (1996)72 | 92 | 2 | C | 36 | 5 | NA |
| Juliusson et al (1996)76 | 52 | 2 | C | 58 | 31 | 20 |
| Rondelli et al (1997)79 | 19 | > 2 | D | 68 | 10 | CR, 9+ |
| Robak et al (2000)74 | 104 | 2 | E | 51 | 15 | 11 |
| Robak et al (2000)74 | 80 | 2 | C | 45 | 9 | 9 |
| Robak et al (2001)73 | 19 | 2 | F, G | 37 | 5 | NA |
| Karlsson et al (2002)78 | 38 | 2 | H | 34 | 5 | 14 |
| Montillo et al (2003)77 | 20 | 2 | I | 35 | 15 | 12 |
| Robak et al (2004)42 | 15 | 2 | J | 73 | 7 | 6 |
| Study . | No. of patients . | Median no. of prior therapies . | Cladribine doses and other agents . | Response, % . | Median duration, mo . | |
|---|---|---|---|---|---|---|
| OR . | CR . | |||||
| Saven et al (1991)71 | 90 | 2 | A, B | 44 | 4 | 4 |
| Tallman et al (1995)75 | 26 | 2 | A | 31 | 0 | 16 |
| Robak et al (1996)72 | 92 | 2 | C | 36 | 5 | NA |
| Juliusson et al (1996)76 | 52 | 2 | C | 58 | 31 | 20 |
| Rondelli et al (1997)79 | 19 | > 2 | D | 68 | 10 | CR, 9+ |
| Robak et al (2000)74 | 104 | 2 | E | 51 | 15 | 11 |
| Robak et al (2000)74 | 80 | 2 | C | 45 | 9 | 9 |
| Robak et al (2001)73 | 19 | 2 | F, G | 37 | 5 | NA |
| Karlsson et al (2002)78 | 38 | 2 | H | 34 | 5 | 14 |
| Montillo et al (2003)77 | 20 | 2 | I | 35 | 15 | 12 |
| Robak et al (2004)42 | 15 | 2 | J | 73 | 7 | 6 |
A indicates 0.1 mg/kg per day as continuous intravenous infusion for 7 days; B, 0.028 to 0.14 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days; C, 0.12 mg/kg per day days 1 to 5 2-hour intravenous bolus; D, 6 mg/m2 per day as 2-hour intravenous infusion for 5 consecutive days; E, 0.12 mg/kg per day 2-hour intravenous infusion for 5 consecutive days + prednisone 30 mg/m2 PO for 5 days; F, 0.12 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days + cyclophosphamide 650 mg/m2 intravenous day 1 + mitoxantrone 10 mg/m2 intravenous day 1; G, 0.12 mg/kg per day as 2-hour intravenous infusion for 3 consecutive days + cyclophosphamide 650 mg/m2 intravenous on day 1 + mitoxantrone 10 mg/m2 intravenous on day 1; H, 10 mg/m2 per day PO for 3 consecutive days every 21 days; I, 4 mg/m2 per day as 2-hour intravenous infusion for 3 consecutive days + cyclophosphamide 350 mg/m2 per day intravenous for 3 days; and J, 0.12 mg/kg per day as 2-hour intravenous infusion for 5 consecutive days, days 2 to 6 + rituximab 375 mg/m2 as 6-hour intravenous infusion day 1; and NA, not available.